Principles and procedures for handling out-of-domain and indeterminate results as part of ICH M7 recommended (Q)SAR analyses.


Journal

Regulatory toxicology and pharmacology : RTP
ISSN: 1096-0295
Titre abrégé: Regul Toxicol Pharmacol
Pays: Netherlands
ID NLM: 8214983

Informations de publication

Date de publication:
Mar 2019
Historique:
received: 14 09 2018
revised: 10 12 2018
accepted: 14 12 2018
pubmed: 19 12 2018
medline: 23 2 2019
entrez: 19 12 2018
Statut: ppublish

Résumé

The International Council for Harmonization (ICH) M7 guideline describes a hazard assessment process for impurities that have the potential to be present in a drug substance or drug product. In the absence of adequate experimental bacterial mutagenicity data, (Q)SAR analysis may be used as a test to predict impurities' DNA reactive (mutagenic) potential. However, in certain situations, (Q)SAR software is unable to generate a positive or negative prediction either because of conflicting information or because the impurity is outside the applicability domain of the model. Such results present challenges in generating an overall mutagenicity prediction and highlight the importance of performing a thorough expert review. The following paper reviews pharmaceutical and regulatory experiences handling such situations. The paper also presents an analysis of proprietary data to help understand the likelihood of misclassifying a mutagenic impurity as non-mutagenic based on different combinations of (Q)SAR results. This information may be taken into consideration when supporting the (Q)SAR results with an expert review, especially when out-of-domain results are generated during a (Q)SAR evaluation.

Identifiants

pubmed: 30562600
pii: S0273-2300(18)30314-3
doi: 10.1016/j.yrtph.2018.12.007
pmc: PMC7500704
mid: NIHMS1517744
pii:
doi:

Substances chimiques

Mutagens 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

53-64

Subventions

Organisme : NIEHS NIH HHS
ID : R44 ES026909
Pays : United States

Informations de copyright

Copyright © 2018 The Authors. Published by Elsevier Inc. All rights reserved.

Références

Regul Toxicol Pharmacol. 2018 Jul;96:1-17
pubmed: 29678766
Regul Toxicol Pharmacol. 2015 Mar;71(2):295-300
pubmed: 25545315
Regul Toxicol Pharmacol. 2015 Jul;72(2):335-49
pubmed: 25980641
Regul Toxicol Pharmacol. 2016 Jun;77:13-24
pubmed: 26877192
Regul Toxicol Pharmacol. 2012 Apr;62(3):449-55
pubmed: 22321701
Mutat Res. 1984 Jul;134(1):1-47
pubmed: 6379432
ALTEX. 2016;33(2):149-66
pubmed: 26863606
J Chem Inf Model. 2012 Oct 22;52(10):2609-18
pubmed: 22947043
SAR QSAR Environ Res. 2016 Nov;27(11):893-909
pubmed: 27827546
Mol Inform. 2010 Jan 12;29(1-2):97-110
pubmed: 27463852
Adv Exp Med Biol. 2016;856:165-187
pubmed: 27671722
J Chem Inf Model. 2014 May 27;54(5):1500-11
pubmed: 24821140
Regul Toxicol Pharmacol. 2015 Apr;71(3):388-97
pubmed: 25656493
Regul Toxicol Pharmacol. 2015 Oct;73(1):367-77
pubmed: 26248005
Regul Toxicol Pharmacol. 2006 Apr;44(3):198-211
pubmed: 16412543
Natl Toxicol Program Tech Rep Ser. 1991 Sep;389:1-165
pubmed: 12637970
Regul Toxicol Pharmacol. 2016 Apr;76:79-86
pubmed: 26785392
Regul Toxicol Pharmacol. 2013 Oct;67(1):39-52
pubmed: 23669331
Altern Lab Anim. 2005 Apr;33(2):155-73
pubmed: 16180989
Ther Innov Regul Sci. 2018 Mar;52(2):244-255
pubmed: 29568713

Auteurs

Alexander Amberg (A)

Sanofi, R&D Preclinical Safety Frankfurt, Industriepark Hoechst, D-65926, Frankfurt am Main, Germany.

Roxanne V Andaya (RV)

Genentech, Inc., 1 DNA Way, South San Francisco, CA, 94080, USA.

Lennart T Anger (LT)

Sanofi, R&D Preclinical Safety Frankfurt, Industriepark Hoechst, D-65926, Frankfurt am Main, Germany.

Chris Barber (C)

Lhasa Limited, Leeds, UK.

Lisa Beilke (L)

Toxicology Solutions Inc., San Diego, CA, USA.

Joel Bercu (J)

Gilead Sciences, 333 Lakeside Drive, Foster City, CA, USA.

Dave Bower (D)

Leadscope, Inc., 1393 Dublin Rd, Columbus, OH, 43215, USA.

Alessandro Brigo (A)

Roche Pharmaceutical Research & Early Development, Pharmaceutical Sciences, Roche Innovation Center Basel, Switzerland.

Zoryanna Cammerer (Z)

Janssen Research & Development, 1400 McKean Road, Spring House, PA, 19477, USA.

Kevin P Cross (KP)

Leadscope, Inc., 1393 Dublin Rd, Columbus, OH, 43215, USA.

Laura Custer (L)

Bristol-Myers Squibb, Drug Safety Evaluation, 1 Squibb Dr, New Brunswick, NJ, 08903, USA.

Krista Dobo (K)

Pfizer Global Research & Development, 558 Eastern Point Road, Groton, CT, 06340, USA.

Helga Gerets (H)

UCB Biopharma SPRL, Chemin du Foriest, B-1420, Braine-l'Alleud, Belgium.

Véronique Gervais (V)

Servier Group, Gidy, France.

Susanne Glowienke (S)

Novartis Pharma AG, Pre-Clinical Safety, Werk Klybeck, CH-4057, Basel, Switzerland.

Stephen Gomez (S)

Consultant to Theravance Biopharma US, Inc., 901 Gateway Blvd, South San Francisco, CA, 94080, USA.

Jacky Van Gompel (J)

Janssen Pharmaceutical Companies of Johnson & Johnson, 2340, Beerse, Belgium.

James Harvey (J)

GlaxoSmithKline, Park Road, Ware, Hertfordshire, SG12 0DP, UK.

Catrin Hasselgren (C)

Genentech, Inc., 1 DNA Way, South San Francisco, CA, 94080, USA.

Masamitsu Honma (M)

National Institute of Health Sciences, Tokyo, Japan.

Candice Johnson (C)

Leadscope, Inc., 1393 Dublin Rd, Columbus, OH, 43215, USA.

Robert Jolly (R)

Toxicology Division, Eli Lilly and Company, Indianapolis, IN, USA.

Raymond Kemper (R)

Vertex Pharmaceuticals Inc., Discovery and Investigative Toxicology, 50 Northern Ave, Boston, MA, USA.

Michelle Kenyon (M)

Pfizer Global Research & Development, 558 Eastern Point Road, Groton, CT, 06340, USA.

Naomi Kruhlak (N)

FDA Center for Drug Evaluation and Research, Silver Spring, MD, USA.

Penny Leavitt (P)

Bristol-Myers Squibb, Drug Safety Evaluation, 1 Squibb Dr, New Brunswick, NJ, 08903, USA.

Scott Miller (S)

Leadscope, Inc., 1393 Dublin Rd, Columbus, OH, 43215, USA.

Wolfgang Muster (W)

Roche Pharmaceutical Research & Early Development, Pharmaceutical Sciences, Roche Innovation Center Basel, Switzerland.

Russell Naven (R)

Takeda, Cambridge, MA, USA.

John Nicolette (J)

AbbVie Inc., North Chicago, IL, USA.

Alexis Parenty (A)

Novartis Pharma AG, Pre-Clinical Safety, Werk Klybeck, CH-4057, Basel, Switzerland.

Mark Powley (M)

Merck Research Laboratories, West Point, PA, 19486, USA.

Donald P Quigley (DP)

Leadscope, Inc., 1393 Dublin Rd, Columbus, OH, 43215, USA.

M Vijayaraj Reddy (MV)

Merck Research Laboratories, West Point, PA, 19486, USA.

Jennifer C Sasaki (JC)

Genentech, Inc., 1 DNA Way, South San Francisco, CA, 94080, USA.

Lidiya Stavitskaya (L)

FDA Center for Drug Evaluation and Research, Silver Spring, MD, USA.

Andrew Teasdale (A)

AstraZeneca, Macclesfield, Cheshire, UK.

Alejandra Trejo-Martin (A)

Gilead Sciences, 333 Lakeside Drive, Foster City, CA, USA.

Sandy Weiner (S)

Janssen Research & Development, 1400 McKean Road, Spring House, PA, 19477, USA.

Dennie S Welch (DS)

AbbVie Inc., North Chicago, IL, USA.

Angela White (A)

GlaxoSmithKline, Park Road, Ware, Hertfordshire, SG12 0DP, UK.

Joerg Wichard (J)

Bayer Pharma AG, Investigational Toxicology, Muellerstr. 178, D-13353, Berlin, Germany.

David Woolley (D)

ForthTox Limited, PO Box 13550, Linlithgow, EH49 7YU, UK.

Glenn J Myatt (GJ)

Leadscope, Inc., 1393 Dublin Rd, Columbus, OH, 43215, USA. Electronic address: gmyatt@leadscope.com.

Articles similaires

Humans Neoplasms Male Female Middle Aged
Humans Patient Reported Outcome Measures Neoplasms Electronic Health Records Delivery of Health Care
Humans Retrospective Studies Male Critical Illness Female
Alzheimer Disease Humans Regression Analysis Quantitative Structure-Activity Relationship Drug Design

Classifications MeSH